November 14, 2003Features
With the necessary tools at hand, the race is on to build — and market — the first affordable, portable, fully functional DNA analyzer. Is the world ready?
By Elizabeth Gardner
How can software developers ensure a share of the tremendous biodefense funding available to bio-IT companies — and what are the risks?
By Jason B. Lee
News·Analysis Merck: We’re So Late We’re EarlyU.K. Prepares to Open World’s Largest BiobankWhen the Chips Are DownIn Silico Studies Shed Light on Immune SystemPublic Library of Science Opens Its DoorsDeCODE Scientists Decode Stroke GeneDedicated Hardware Pushes Speed LimitsEyes on the In Silico PrizeSenate Finally Passes Genetic Nondiscrimination BillHorizons
Peter Corr on IT, clinical trials, and his -billion budget.
New tools and business structures show signs of plumping early-stage pipelines.
On-demand computing services provide an alternative to buying the server farm.
Consolidation slows, valuations grow, and now hope for some IPOs.Columns
| Kevin Davies
Paul Allen's new brain institute blazes a trail.
| Michael A. Greeley
How much compensation is "appropriate"?
| By Julia Boguslavsky
454's genome center in a box.
| By John Russell
A visit to Shanghai, China's future capital of biotech. Departments
PerkinElmer goes further with imaging · ABI displays Affinity for analysis · OctigaBay multiprocessor system aims to eliminate computing bottlenecks.